Declaration of Financial results for the quarter and year ending 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syschem (India) Limited reported audited standalone results for FY25 with revenue from operations rising sharply to ₹386.23 crore from ₹233.48 crore in FY24, a growth of about 65%. However, profit before tax fell steeply to ₹1.01 crore from ₹4.11 crore, and profit after tax dropped to ₹46.01 lakh from ₹2.76 crore, reflecting heavy margin compression despite the strong top-line growth. The company raised ₹33.87 crore via a preferential issue in February-March 2025, partly deployed for working capital. Total financial indebtedness remains zero with no loan defaults reported, and cash and bank balances improved to ₹2.14 crore from ₹9.57 lakh a year ago.
Strong revenue growth signals business expansion, but the sharp drop in profit and negative operating cash flow (₹10.09 crore used in operations) suggest cost pressures and working-capital strain, which may concern shareholders looking at profitability rather than just top-line numbers.